Janux Therapeutics (JANX) Common Equity (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Common Equity data on file, last reported at $941.5 million in Q1 2026.

• Common Equity for Q1 2026 came in at $941.5 million, down 7.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $941.5 million (down 7.01% YoY), and the FY2025 annual result was $956.8 million, down 6.45% from the prior year.
• Common Equity fell to $941.5 million in Q1 2026 per JANX's latest filing, from $956.8 million in the prior quarter.
• Over five years, Common Equity peaked at $1.0 billion in Q4 2024 and troughed at $299.5 million in Q2 2023.
• A 5-year average of $619.2 million and a median of $655.8 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity soared 2223.2% in 2022, then slipped 12.9% in 2023.
• A 5-year view of Common Equity shows it stood at $320.7 million in 2022, then increased by 7.36% to $344.3 million in 2023, then surged by 197.02% to $1.0 billion in 2024, then slipped by 6.45% to $956.8 million in 2025, then dropped by 1.6% to $941.5 million in 2026.
• Business Quant data shows JANX's Common Equity at $941.5 million in Q1 2026, $956.8 million in Q4 2025, and $976.6 million in Q3 2025.